Page 142 - CW E-Magazine (14-1-2025)

Pharmaceuticals Pharmaceuticals

EXPANSION BUSINESS RESTRUCTURING
Macsen Labs begins work on new API facility Sun Pharma sells entire stake in Japanese arm

in Udaipur to Zaza Industrial Holdings

Macsen Labs Group, a Rajasthan- city of 100-KL (both stain- Sun Pharmaceutical Industries has diary operates a manufacturing plant
based manufacturer of active pharma- less steel & glass-lined reac- announced the 100% sale of its step- in Saitama, Japan, which produces
ceutical ingredients (APIs), dyes, fi ne & tors); a new dedicated R&D down subsidiary, Sun Pharma Japan products for Sun Pharma Japan. The
speciality chemicals, has commenced centre over an area of 15,000 Technical Operations Limited, to Zaza plant will continue to supply products
of construction of its new APIs manu- sq ft; and an advanced pilot Industrial Holdings K.K., Japan. to Sun Pharma under a contract valid
facturing facility near its existing unit, plant which will enable till May 2026.
Macsen Drugs, in Udaipur. pilot-scale production of APIs The decision marks a strategic
and commercial production move by the company, which operates The buyer, Zaza Industrial Holdings
Spread over 25,000 square metres, of low-volume, pre-clinical one of the largest pharmaceutical busi- The turnover of Sun Pharma Japan K.K., is a Japan-based company with
the new facility is fi ve times larger and clinical trial APIs. nesses globally. According to a regula- Technical Operations Limited contri- no affi liation to Sun Pharma’s promoter
than the current infrastructure at tory fi ling with BSE, the agreement was buted less than 0.5% to Sun Pharma’s group. The move to divest the subsi-
Macsen Drugs, which is a USFDA “We also have plans signed on December 31, 2024, with consolidated turnover in 2023-24, diary aligns with the company’s broader
inspected, TGA-GMP, and WHO-GMP applications,” the company said in a to install a special production line transaction expected to be completed and has been sold for a nominal strategy to optimise its global opera-
certified manufacturing unit. press note. for manufacturing & performing cor- by January 31, 2025. consideration of JPY 1. The subsi- tions.
“Designed to support scalability and rosive chemistries with Hastelloy,
operational effi ciency, the new facility Macsen plans to invest approxi- Halar-coated equipment, etc,” said Fire at pharma plant of RPG Life Sciences:
will include multiple API production mately Rs. 75-crore in the initial phase Mr. Achal Agrawal, Chairman and CEO
blocks capable of handling diverse of development, which will include of Macsen Group. “We aim to commence
and advanced manufacturing processes two multistorey API production blocks production activities at this new facility A fi re broke out within one of the … and at Black Rose Industries tion at the affected site and therefore,
In another development, a Black there is no impact on the business opera-
for APIs for various therapeutic equipped with a combined reactor capa- by the end of 2025,” he added. manufacturing units of the Pharma Plant
of RPG Life Sciences, located at Plot No. Rose Industries Ltd., a leading supplier tions or functions of the company. The
25/25A, MIDC, Thane-Belapur Road, of acrylamide, has reported a fi re inci- loss is only related to the value of the
Divi’s Labs begins operations at fi rst phase Navi Mumbai, on January 2, 2025. dent at Building No. 2, Plot No. 11-18, building. The asset impacted by the fi re
Shree Laxmi Co-op. Industrial Estate is fully insured, and the company has
of Kakinada greenfi eld project mately 9:00 am, while causing consi- Ltd., Hatkanangle, Dist. Kolhapur, already taken the necessary steps to fi le
The fi re which occurred, at approxi-
which is owned by the company. “We an insurance claim to cover the loss and
derable disruption, resulted in no injuries would like to clarify that the company damage caused by the incident,” it said
Hyderabad-based Divi’s Labora- suits with a total or loss of human life. was not carrying out any of its opera- in a statement.
tories Ltd. has started commercial reaction capacity of
operations at its Kakinada plant in more than around
Andhra Pradesh from January 1, 14,500 m³, making Alkem Laboratories sells MP facility to Rubicon
2025, as per a stock market filing. it one of the largest
The operations are a part of phase active pharmaceuti- Research
one of Unit 3 of the greenfield pro- cal ingredients manu-
ject at Ontimamidi Village (Kona) in facturing facilities Mumbai-based Alkem Labora- Special Economic Zone in
Thondangi Mandal, Kakinada. in the world. tories Ltd. has announced the sale of Pithampur alongwith all
its manufacturing facility in Pithampur, rights, title and interest in
The phase one of the ‘Export The third manu- Madhya Pradesh to Rubicon Research the leasehold land, factory
Oriented Unit’ is being implemen- facturing site near Ltd. for Rs. 149-crore. building, assets and liabi-
ted on 200 acres of the 500-acre Kakinada has been lities.
Unit III site, with an estimated in- in the works since As per a stock market fi ling, the
vestment between Rs. 1,200-crore 2021. The company deal was carried out on a slump sale Alkem said the move is
and Rs. 1,500-crores, according to two manufacturing sites near is a commercial-scale manufacturer basis pursuant to a business transfer part of its “ongoing initia-
the filing. Hyderabad and Visakhapatnam. Both the of non-potent and highly potent agreement executed between the par- tive of networking strategy
manufacturing units have more than 64 APIs as well as several low-dose ties on January 6, 2025. The deal and optimisation of manu-
Divi’s Labs currently operates production buildings and 70 pharma products. includes the facility located at the facturing facilities”.

142 Chemical Weekly January 14, 2025 Chemical Weekly January 14, 2025 143

Contents Index to Advertisers Index to Products Advertised